These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11295630)

  • 41. Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Nov; 81(226):84465-77. PubMed ID: 27906534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
    [No Abstract]   [Full Text] [Related]  

  • 43. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Surrogate endpoints and FDA's accelerated approval process.
    Fleming TR
    Health Aff (Millwood); 2005; 24(1):67-78. PubMed ID: 15647217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reevaluating the accelerated approval process for oncology drugs.
    Wilson WH; Schenkein DP; Jernigan CL; Woodcock J; Schilsky RL
    Clin Cancer Res; 2013 Jun; 19(11):2804-9. PubMed ID: 23553847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
    Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
    JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New FDA breakthrough-drug category--implications for patients.
    Ricart AD
    N Engl J Med; 2014 Jul; 371(1):89. PubMed ID: 24988580
    [No Abstract]   [Full Text] [Related]  

  • 50. New FDA breakthrough-drug category--implications for patients.
    Velleca M
    N Engl J Med; 2014 Jul; 371(1):88-9. PubMed ID: 24988579
    [No Abstract]   [Full Text] [Related]  

  • 51. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576
    [No Abstract]   [Full Text] [Related]  

  • 52. New FDA breakthrough-drug category--implications for patients.
    Murray BE
    N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578
    [No Abstract]   [Full Text] [Related]  

  • 53. New FDA breakthrough-drug category--implications for patients.
    McClellan M; Sigal E
    N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577
    [No Abstract]   [Full Text] [Related]  

  • 54. Oncology drug development: United States Food and Drug Administration perspective.
    Hirschfeld S; Pazdur R
    Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 56. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
    Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.
    Lee JY; Garnett CE; Gobburu JV; Bhattaram VA; Brar S; Earp JC; Jadhav PR; Krudys K; Lesko LJ; Li F; Liu J; Madabushi R; Marathe A; Mehrotra N; Tornoe C; Wang Y; Zhu H
    Clin Pharmacokinet; 2011 Oct; 50(10):627-35. PubMed ID: 21895036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 60. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.